These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29464969)

  • 1. Clostridioides (Clostridium) difficile infection: current and alternative therapeutic strategies.
    Gil F; Calderón IL; Fuentes JA; Paredes-Sabja D
    Future Microbiol; 2018 Mar; 13():469-482. PubMed ID: 29464969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonantimicrobial drug targets for Clostridium difficile infections.
    Darkoh C; Deaton M; DuPont HL
    Future Microbiol; 2017 Sep; 12(11):975-985. PubMed ID: 28759258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clostridioides difficile Infection.
    Guh AY; Kutty PK
    Ann Intern Med; 2018 Oct; 169(7):ITC49-ITC64. PubMed ID: 30285209
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Domestic canines do not display evidence of gut microbial dysbiosis in the presence of Clostridioides (Clostridium) difficile, despite cellular susceptibility to its toxins.
    Stone NE; Nunnally AE; Jimenez V; Cope EK; Sahl JW; Sheridan K; Hornstra HM; Vinocur J; Settles EW; Headley KC; Williamson CHD; Rideout JR; Bolyen E; Caporaso JG; Terriquez J; Monroy FP; Busch JD; Keim P; Wagner DM
    Anaerobe; 2019 Aug; 58():53-72. PubMed ID: 30946985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is fecal microbiota transplantation a temporary patch for treatment of Clostridium difficile infection or a new frontier of therapeutics?
    Khoruts A
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):435-438. PubMed ID: 29667436
    [No Abstract]   [Full Text] [Related]  

  • 6. Acyldepsipeptide antibiotics as a potential therapeutic agent against Clostridium difficile recurrent infections.
    Gil F; Paredes-Sabja D
    Future Microbiol; 2016 Sep; 11():1179-89. PubMed ID: 27546386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cationic biaryl 1,2,3-triazolyl peptidomimetic amphiphiles targeting Clostridioides (Clostridium) difficile: Synthesis, antibacterial evaluation and an in vivo C. difficile infection model.
    Tague AJ; Putsathit P; Hutton ML; Hammer KA; Wales SM; Knight DR; Riley TV; Lyras D; Keller PA; Pyne SG
    Eur J Med Chem; 2019 May; 170():203-224. PubMed ID: 30901686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update of treatment algorithms for Clostridium difficile infection.
    Ooijevaar RE; van Beurden YH; Terveer EM; Goorhuis A; Bauer MP; Keller JJ; Mulder CJJ; Kuijper EJ
    Clin Microbiol Infect; 2018 May; 24(5):452-462. PubMed ID: 29309934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clostridium difficile drug pipeline: challenges in discovery and development of new agents.
    Jarrad AM; Karoli T; Blaskovich MA; Lyras D; Cooper MA
    J Med Chem; 2015 Jul; 58(13):5164-85. PubMed ID: 25760275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interactions between intestinal microbiota and Clostridioides difficile].
    Barbut F; Couturier J
    Rev Prat; 2019 Sep; 69(7):784-791. PubMed ID: 32233325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What do we know about the diagnostics, treatment and epidemiology of Clostridioides (Clostridium) difficile infection in Europe?
    Nagy E
    J Infect Chemother; 2018 Mar; 24(3):164-170. PubMed ID: 29289484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use your antibiotics wisely. Consequences to the intestinal microbiome.
    Cervantes J
    FEMS Microbiol Lett; 2016 May; 363(10):. PubMed ID: 27044298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The development of live biotherapeutics against
    Zhang Y; Saint Fleur A; Feng H
    Gut Microbes; 2022; 14(1):2052698. PubMed ID: 35319337
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel approaches to treating Clostridium difficile-associated colitis.
    Padua D; Pothoulakis C
    Expert Rev Gastroenterol Hepatol; 2016; 10(2):193-204. PubMed ID: 26643655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current developments in lantibiotic discovery for treating Clostridium difficile infection.
    Sandiford SK
    Expert Opin Drug Discov; 2019 Jan; 14(1):71-79. PubMed ID: 30479173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DAV131A Protects Hamsters from Lethal
    Saint-Lu N; Burdet C; Sablier-Gallis F; Corbel T; Nevière A; Sayah-Jeanne S; Pulse M; Weiss W; Ferreira S; Andremont A; Mentré F; de Gunzburg J
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31636067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential for emerging therapeutic options for Clostridium difficile infection.
    Mathur H; Rea MC; Cotter PD; Ross RP; Hill C
    Gut Microbes; 2014; 5(6):696-710. PubMed ID: 25564777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ridinilazole for the treatment of Clostridioides difficile infection.
    Carlson TJ; Endres BT; Bassères E; Gonzales-Luna AJ; Garey KW
    Expert Opin Investig Drugs; 2019 Apr; 28(4):303-310. PubMed ID: 30767587
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridioides difficile infection.
    Brown JR; Flemer B; Joyce SA; Zulquernain A; Sheehan D; Shanahan F; O'Toole PW
    BMC Gastroenterol; 2018 Aug; 18(1):131. PubMed ID: 30153805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Oncologic aspects of Clostridium difficile].
    Telekes A
    Orv Hetil; 2016 Jul; 157(28):1110-6. PubMed ID: 27397423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.